和誉-B：口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has received FDA approval for the IND application of a new oral, highly active, and selective small molecule KRAS G12D inhibitor, ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The new drug ABSK141 targets advanced solid tumors with KRAS G12D mutations [1] - The FDA approval marks a significant milestone for the company's research and development efforts in oncology [1] - The development of ABSK141 reflects the growing focus on targeted therapies in cancer treatment [1]